anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
This is a phase 3, multicenter, double-blind, placebo-controlled, parallel group, randomized, 24-week study to evaluate the safety and efficacy of Certolizumab Pegol (CZP) as additional medication to Methotrexate (MTX) in Chinese subjects with active Rheumatoid Arthritis (RA) who have an incomplete response to Methotrexate. This study is designed to determine whether CZP 400 mg at Weeks 0, 2, and 4 followed by CZP 200 mg every 2 weeks (Q2W) in combination with MTX demonstrates superiority, in terms of greater improvement in relief of the signs and symptoms of RA, compared with MTX alone. Approximately 535 subjects will be screened to randomize 400 subjects into this study, at approximately 25 centers in the People's Republic of China. There will be 2 treatment groups, with 300 subjects in the CZP+MTX group and 100 subjects in the PBO+MTX group. For each subject, the study duration will last a maximum of approximately 38 weeks. Subjects who complete study RA0044 and subjects who fail to achieve an American College of Rheumatology 20 % Response Criteria (ACR20) response at Week 12 that is confirmed at Week 14 and thus are withdrawn from this study at Week 16, are permitted to receive treatment with CZP in the open-label extension study, RA0078. The secondary objectives are to assess the dose regimen of CZP in combination with MTX compared with MTX alone in the safety and tolerability, ability to improve physical function, and health outcomes measures in Chinese subjects with active RA; also to characterize the pharmacokinetic (PK) profile and immunogenicity of CZP in combination with MTX.
Patients meeting inclusion criteria will be enrolled while they are here on campus for a regular clinic visit. Once they consent, they will complete a baseline survey, and will be given the FCAD with the instruction manual and the investigators will go over how to use the device and answer any questions. The PI will be available throughout the study for any questions that may arise. Participants will use the device for their regular enemas for up to 4 weeks. If the device is negatively impacting enema administration, they can choose to stop using the device at any time but it is preferable that participants use the device five times before they decide it is not working for them. Once a participant has used the device for 4 weeks or has chosen to opt out of completing the 4-week trial, they will complete a second survey. The baseline survey will assess how current enema administration practices are going and the second survey will assess how well enema administration is going while using the device. If time allows and user feedback indicates a need, the device will be modified, and participants asked to use the second version for up to 4 weeks. Again, if the device is negatively impacting enema administration, they can choose to stop using the second version of the device at any time but it's preferable that participants use it five times before deciding it is not working for them. Once a participant has used the second version of the device for 4 weeks, or chosen to opt out of completing the 4-week trial, they will complete a third survey assessing the second version of the device. If traveling to CHCO is not convenient, the second version of the device will be mailed to the participant and they will complete the surveys via email or over the phone. This eliminates the need for a return trip to CHCO. REDCap will be used for all surveys. If participants are not able to complete the surveys electronically for any reason, they will complete a hardcopy version, or the survey will be administered over the phone, whichever is convenient for the participant.
PURPOSE: To evaluate using a biocellulose-based hydrogel as an adjuvant in the healing process of arterial ulcers.
METHODS: A prospective single group quasi-experimental study was carried out with chronic lower limb arterial ulcer patients. These patients received biocellulose-based hydrogel dressings and outpatient guidance on dressing and periodic reassessments. The primary outcomes were the ulcer-healing rate and product safety, which were assessed by ulcer area measured in photographic records of pre-treatment and posttreatment after 7, 30, and 60 days. Secondary outcomes were related to clinical assessment by the quality-of-life scores (SF-36 and EQ-5D) and pain, evaluated by the visual analogue scale (VAS).
RESULTS: Seventeen participants were included, and one of them was excluded. Six patients (37%) had complete wound healing, and all patients had a significant reduction in the ulcer area during follow-up (233.6mm2 versus 2.7mm2) and reduction on the score PUSH 3.0 (p < 0.0001). The analysis of the SF-36 and EQ-5D questionnaires showed a statistically significant improvement in almost all parameters analyzed and with a reduction of pain assessed by the VAS.
CONCLUSIONS: The biocellulose-based hydrogel was safe and showed a good perspective to promoting the necessary conditions to facilitate partial or complete healing of chronic arterial ulcers within a 60-day follow-up. Quality of life and pain were positively affected by the treatment.
The study included a total of 1138 patients who underwent lung resection in investigators's hospital from 2017 to 2022. Patients who underwent surgery between 7 and 11 ante meridiem (AM) versus between 12 and 5 post meridiem (PM) were compared regarding the incidence of PPCs and postoperative AEs. The patients' data were obtained from the electronic surgical case system and intraoperative anaesthesia records by professionals in the Big Data Center of the First Affiliated Hospital of Shandong First Medical University. Using medical record numbers and dates of surgery, investigators collected the following information: sex, age, height, weight, American Society of Anesthesiologists classification, complications, anesthesia and surgery duration, postoperative analgesia, type of operation, selective surgery, intraoperative blood transfusion, progress notes, postoperative imaging (e.g., chest X-ray, computed tomography) and related laboratory test results. Patients were stratified by morning or afternoon surgery. All data analyses were performed using open source statistical computing software (R, version 4.1.2; www.r-project.org). Categorical variables were expressed as frequencies and percentages, and comparisons between groups were performed using either the X² or Fisher's exact tests. Continuous variables were expressed as mean±standard deviation or median \[interquartile range\] according to whether the data conformed to a normal distribution. The independent samples t-test was used for comparisons between groups for normally distributed data, and the Mann--Whitney U test was used for non-normally distributed data. By convention, two-sided statistical significance was assumed, with P\<0.05. For variables with a missing data rate of \< 25% , investigators used multiple imputations by chained equations to meet the statistical requirements.

To check the consistency of the findings, co-variate balancing propensity score matching was performed. In the propensity score matching, investigators used nearest neighbour matching with a specified caliper distance (0.25) to minimise the potential impact of differences in the baseline variables on the endpoints. In accordance with the Assess Respiratory Risk in Surgical Patients in Catalonia system, patients in the morning surgery group were matched 1:1 with patients in the afternoon surgery group regarding age, weight, American Society of Anesthesiologists classification, smoking, chronic obstructive pulmonary disease, hypertension, coronary heart disease, preoperative anaemia, diabetes, type of surgery, duration of surgery, selective surgery, and intraoperative blood transfusion. Investigators also performed a sensitivity analysis according to the department of presentation (Thoracic Surgery I and Thoracic Surgery II) and type of surgery to verify the robustness of the statistical analysis results.
Bacterial vaginosis (BV) is characterized by an imbalance in the normal vaginal bacterial flora. In the United States (US), BV is very common, and the most common cause of vaginitis, affecting approximately 1 in 10 sexually active young women. Because BV is so common, interventions targeting BV could have a tremendous public health impact. This is a phase III randomized controlled trial, in which the primary objective is to determine whether regular screening (every two months) and treatment for asymptomatic BV can reduce the one-year incidence of chlamydial and gonococcal infections, compared to a control group of women who receive regular monitoring (every two months) for BV but no treatment. The secondary study objective is to determine demographic and behavioral factors associated with the acquisition of BV, its persistence among women who are not treated for this condition, its spontaneous resolution, and its recurrence in women who are treated for this condition. This study protocol will enroll 1500 sexually active females, aged 15 - 25 years, from 6 US cities involved in the Sexually Transmitted Infections Clinical Trials Group network (Birmingham, Durham, Raleigh, Pittsburgh, Baltimore and San Francisco). To be eligible, women must have 2 or more risk factors for sexually transmitted diseases (STDs) and must have clinical evidence of asymptomatic BV at enrollment. For the purposes of this study, women with a vaginal pH\>4.5 with \>20 percent clue cells detected by microscopy to have asymptomatic BV. In addition, women must deny the presence of unusual or abnormal vaginal discharge or odor. Subjects will receive bi-monthly (every two months) home self-testing kits for BV using a vaginal swab. If BV is detected by self-test, the subjects in the intervention group will receive antibiotic treatment consisting of metronidazole 500mg twice daily for 7 days. Subjects will be randomized to either an intervention group (screening and treatment for BV) or a control group (monitoring for BV without treatment). Subjects in both the intervention group and the control group will complete bi-monthly (every 2 months) follow-up assessments for BV at months 2, 4, 6, 8, 10, and 12 (the final follow-up). In addition, subjects will provide sample collections for Chlamydia trachomatis and Neisseria gonorrhoeae at 4, 8, and 12 months after study entry.
PURPOSE: A smoking cessation aid composition containing damascone is provided to ensure similar taste and flavor with tobacco and to help smoking cessation. CONSTITUTION: A smoking cessation aid composition contains 0.001-10 wt% of damascone and 90.99.999 wt% of propylene glycol. A smoking cessation aid contains 0.001-10 wt% of damascene, 30-90 wt% of propylene glycol, and 5-60 wt% of glycerin. The damascone includes alpha-damascone, beta-damascone, or delta-damascone. The composition additionally contains 0.001-10 weight parts of vitamins or amino acids, aroma or fruit perfume. contains the flavor of strawberry, melon, peach, blueberry, banana, lemon, mango, apple, orange, kiwi, pineapple, or grape.
Patients in the standard statin arm will continue to receive atorvastatin 20 mg/day or rosuvastatin 10 mg/day. Statin dose escalation or adding concomitant non-statin lipid-lowering therapy could be considered by their responsible physician to achieve an LDL-C target \<100 mg/dL.
The system provides true two integration of web provided data into a practice management system. The system builds a web site on a host system and transmits input data from the web site to a remote computer system. The input data is any information provided by a patient to the web site. Additionally, the host system receives display data from a remote computer system. Each practice or remote system provides the display data for its patients. The display data typically consists of patient account information. When a web site receives a request from a patient, the host system retrieves that individuals data for display on the web site.
PROBLEM TO BE SOLVED: To obtain a medicinal composition which increases sustainability of an active ingredient in blood, possesses excellent movalility to tissues and is effective for improvement of a variety of nervous symptoms by combination of a vitamin B1 derivative or its salt and a specific compound. SOLUTION: As this composition, a vitamin B1 derivative or its salt and idebenone are simultaneously used. By this combination, conversion of the vitamin B1 derivative or its salt absorbed from digestive tract into thiamine with SH compounds in blood is suppressed and movement to target tissues such as nervous tissues is increasable. The vitamin derivative (salt) and idebenone are formulated in amounts of 1-500 pts.wt. and 1-500 pts.wt., respectively. As the salt of vitamin B1 derivative, fursultiamine hydrochloride is particularly preferable. This medicinal composition is particularly effective for nervous symptoms caused by Alzheimer's disease.
Ventilation systems of operating rooms (ORs) are significantly important in preventing postoperative wound infections that can cause morbidity and mortality after surgery in or out of the hospital. This study aims to identify the optimum overpressure for efficient operation while reducing the risk of surgical site infections (SSIs) based on the actual OR with the help of computational fluid dynamics. The species transport model, Lagrangian discrete phase model, and turbulent standard k- ε model are mainly used for the transient numerical study to improve the performance of the OR and reduce SSI cases. Four OR schemes were initially calculated for the best location of the patient on the surgical table. The results revealed that the modified position 90˚ is the best location with the minimum CO2 and BCP concentrations. The investigated operating room could host up to ten surgical members with the optimum overpressure of 5.89 Pa and 0.56 m/s of supply velocity under the standard cleanliness level. Modifying the supply surface area will enhance the performance of the operating room by providing a cleaner zone and maintaining the desired room pressure, even with a low airflow rate. This optimization scheme could guide practical applications in all positively pressurized operating rooms to address issues related to overpressure effects.
Patients with Huntington’s disease are at increased risk for depression, suicidal ideation or behaviors (suicidality). XENAZINE increases the risk for suicidality in patients with HD. 

In a 12-week, double-blind, placebo-controlled study in patients with chorea associated with Huntington’s disease, 10 of 54 patients (19%) treated with XENAZINE were reported to have an adverse event of depression or worsening depression compared to none of the 30 placebo-treated patients. In two open-label studies (in one study, 29 patients received XENAZINE for up to 48 weeks; in the second study, 75 patients received XENAZINE for up to 80 weeks), the rate of depression/worsening depression was 35%. 

In all of the HD chorea studies of XENAZINE (n=187), one patient committed suicide, one attempted suicide, and six had suicidal ideation. 

When considering the use of XENAZINE, the risk of suicidality should be balanced against the need for treatment of chorea. All patients treated with XENAZINE should be observed for new or worsening depression or suicidality. If depression or suicidality does not resolve, consider discontinuing treatment with XENAZINE. 

Patients, their caregivers, and families should be informed of the risks of depression, worsening depression, and suicidality associated with XENAZINE, and should be instructed to report behaviors of concern promptly to the treating physician. Patients with HD who express suicidal ideation should be evaluated immediately.
The present invention is a topical composition comprising (a) L-carnitine, an acyl L-carnitine, a salt thereof, or a mixture thereof and (b) one or more hydroxy acids, proteolytic enzymes, skin lightening agents, or a mixture thereof, in a pharmacologically acceptable vehicle for topical application. The topical composition may be administered to improve or prevent deleterious skin conditions (e.g., epidermal exfoliation and loss of skin elasticity), exfoliate skin, accelerate skin turnover, and/or lighten skin. For example, it can be administered to minimize scar formation due to varicella infection, drying and peeling due to sunburn, and to improve skin elasticity. The topical composition preferably has a pH ranging from about 3.5 to about 8. According to one embodiment, the pH of the topical composition ranges from about 3.5 to about 6.5 or 7. According to another embodiment, the pH of the topical composition ranges from about 6 to about 8 and preferably from about 6.5 to 7.5. According to one preferred embodiment, the topical composition is preferably substantially free of D-carnitine, acyl D-carnitine, and salts thereof and, more preferably, is further substantially free of LD-carnitine, acyl LD-carnitine, and salts thereof.
Participants will receive single doses of niraparib and AA using niraparib Formulation 3 as Treatment C in Treatment Period 1, followed by Treatment B in Treatment Period 2, followed by Treatment D in Treatment Period 3. From Period 2 onwards and during Extension and Long-term Extension Phases, all participants will continue to receive treatment with niraparib and AAP or AAP alone.
The research follows on from a pilot study that took place at the Department of Rehabilitation and Sports Medicine, University Hospital Ostrava from 4/2022 to 9/2022. It has a prospective monocentric randomized trial design. Patients will be randomized into parallel groups - intervention and control groups.

A prospective monocentric randomized study lasting 8 months at the Department of Rehabilitation and Sports Medicine, University Hospital Ostrava. The study design is parallel with a test and control arm. Patients will be divided into an intervention (tested) group A with therapy on Armeo Spring and a control group B with conventional therapy, using a random number generator, where odd numbers represent arm A and even numbers represent arm B. A randomization table randomly allocates patients to therapy according to their order of entry into the study.
This study is comprised of two phases. In the first phase of the study, we will test associations between participation in combinations of 6 intervention components reflecting differing levels of practical resources to increase the frequency of healthy family mealtimes, improve children's dietary quality and ultimately reduce childhood obesity prevalence. Phase 1 utilizes the Multiphase Optimization Strategy (MOST) design to test combinations of the 6 intervention components which include: (1) Meal Delivery: the home delivery of pre-made healthy family meals including recipes weekly (2) Ingredient Delivery: the home delivery of ingredients and recipes to make healthy family meals weekly; (3) Community Kitchen: community kitchen sessions in which families prepare healthy meals with recipes to take home weekly; (4) Didactics: nutrition education classes using the Preschool Obesity Prevention Series (POPS) curriculum (5) Cooking Lessons: cooking lessons/demonstrations with recipes weekly; and (6) Cookware/Flatware: delivery of flatware/ cookware to utilize for family meals delivered at the beginning of the intervention. The goal of Phase 1 is to identify the intervention components most robustly related to decreased BMI z-score, increased dietary quality and frequency of family meals. Phase 1 will enroll approximately 500 parents of preschoolers. The goal of Phase 2 is to test the selected intervention components (identified in Phase 1) in a randomized controlled trial with approximately 250 participants. Participants in both phases will be enrolled through Head Start programs and/or university research recruitment platforms, social media, and posted flyers. The intervention period in Phase 1 will be 8 weeks, and the intervention period in Phase 2 will be expanded to 12 weeks.
An O-derivatized alginic acid antigen capable of eliciting opsonizing antibodies in vivo is described. The O-derivatized antigen shows enhanced antigenicity and immunogenicity relative to native, non-O-derivatized alginic acid antigens, particularly the MEP antigen of P. aeruginosa. Pharmaceutical compositions containing the O-derivatized antigen of the invention are also described. The invention also pertains to use of the compositions as vaccines, in immunodiagnostic assays, and in methods for producing monoclonal antibodies reactive against the antigen. Methods for forming O-derivatized alginic acid antigens of the invention are described. A non-O-derivatized starting material is reacted in a solvent with an alkyl anhydride derived from a fatty acid.
1. A method for damaging thermo non-tolerant pathologic biostructures of an organism by total controlled hyperthermia, consisting in heating the organism by immersing it, apart from the head, in a thermal liquid under the conditions its forced convection with the use of anesthetic means, means for antishock therapy and artificial lung ventilation, and with suppression of the total proteolytic activity in the blood, wherein said heating is performed at the thermal liquid temperature of 44 to 48 degree C until obtaining the organism temperature of 42.0 to 44.5 degree C, said suppression of the total proteolytic activity in the blood being performed by controlling the organism heating rate and by carrying out a continuous infusion of at least one solution of an agent belonging to the antiproteinase class in an efficient amount during the heating. 2. A method as claimed in claim 1, wherein said heating of the organism is carried out at a rate of not less than 1 degree C per 5.5 minutes. 3. A method as claimed in claim 1 or 2, wherein said solutions for infusion represent a hexamethylenetetramine solution at a rate of (2 to 6) mg/kg/min ad a pyridoxine solution at a rate at least 0.2 mg/kg/min. 4. A method as claimed in any claim 1, 2 or 3, wherein a high-frequency artificial lung ventilation providing for a saturation of 95 to 100% is used.
Selenium (Se) deficiency can affect the expression of microRNA (miRNA) and induce necroptosis, apoptosis, etc., resulting in damage to various tissues and organs. Bisphenol A (BPA) exposure can cause adverse consequences such as oxidative stress, endothelial dysfunction, and atherosclerosis. The toxic effects of combined treatment with Se-deficiency and BPA exposure may have a synergistic effect. We replicated the BPA exposure and Se-deficiency model in broiler to investigate whether the combined treatment of Se-deficiency and BPA exposure induced necroptosis and inflammation of chicken vascular tissue via the miR-26A-5p/ADAM17 axis. We found that Se deficiency and BPA exposure significantly inhibited the expression of miR-26a-5p and increased the expression of ADAM17, thereby increasing reactive oxygen species (ROS) production. Subsequently, we discovered that the tumor necrosis factor receptor (TNFR1), which was highly expressed, activated the necroptosis pathway through receptor-interacting protein kinase 1 (RIPK1), receptor-interacting protein kinase 3 (RIPK3), and mixed-lineage kinase domain-like (MLKL), and regulated the heat shock proteins-related genes expressions and inflammation-related genes expressions after exposure to BPA and selenium deficiency. In vitro, we found that miR-26a-5p knockdown and increased ADAM17 can induce necroptosis by activating the TNFR1 pathway. Similarly, both N-Acetyl-L-cysteine (NAC), Necrostatin-1 (Nec-1), and miR-26a-5p mimic prevented necroptosis and inflammation caused by BPA exposure and Se deficiency. These results suggest that BPA exposure activates the miR-26a-5p/ADAM17 axis and exacerbates Se deficient-induced necroptosis and inflammation through the TNFR1 pathway and excess ROS. This study lays a data foundation for future ecological and health risk assessments of nutrient deficiencies and environmental toxic pollution.